(JREB) JPMorgan s Ireland ICAV - Ratings and Ratios

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: IE00BF59RX87

Corporate Bonds, European Securities, Fixed Income

Description: JREB JPMorgan s Ireland ICAV

The JPMorgan ETFs Ireland ICAV - EUR Corporate Bond Research Enhanced Index ESG UCITS ETF EUR Acc is an exchange-traded fund (ETF) listed on XETRA with the ticker symbol JREB. It is designed to track the Morningstar EZN Corp Bd GR EUR index, providing exposure to EUR-denominated corporate bonds.

As an ETF in the EUR Corporate Bond category, JREB offers investors a diversified portfolio of high-quality corporate bonds with a focus on ESG (Environmental, Social, and Governance) considerations. The funds assets under management (AUM) stand at approximately €5.987 billion, indicating a significant presence in the market.

From a technical analysis perspective, JREBs price is currently at €107.15, with a 20-day simple moving average (SMA) of €106.79 and a 50-day SMA of €106.39, suggesting a positive short-term trend. The 200-day SMA at €105.20 indicates a longer-term uptrend. The average true range (ATR) is €0.24, representing a relatively low volatility of 0.22%. The funds price has reached a 52-week high of €107.15 and a low of €101.14, demonstrating a notable range.

To further evaluate JREBs performance, key performance indicators (KPIs) such as yield, duration, and credit quality can be examined. The funds yield, which is a critical metric for income-focused investors, is not explicitly stated; however, it can be inferred that the yield is likely to be in line with the overall EUR corporate bond market. The duration of the fund, which measures its sensitivity to interest rate changes, is also not provided; nonetheless, it is expected to be relatively high given the funds focus on corporate bonds. Credit quality is another essential KPI, with a higher proportion of high-quality bonds typically indicating lower default risk.

Additional KPIs that can be used to assess JREBs performance include its tracking error, expense ratio, and ESG metrics. The tracking error measures the funds ability to replicate the performance of its underlying index, while the expense ratio reflects the costs associated with managing the fund. ESG metrics, such as the funds carbon footprint or ESG rating, can provide insights into its sustainability and social responsibility profile.

Additional Sources for JREB ETF

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

JREB ETF Overview

Market Cap in USD 6,995m
Category EUR Corporate Bond
IPO / Inception 2018-12-05

JREB ETF Ratings

Growth Rating 6.94
Fundamental -
Dividend Rating 0.0
Rel. Strength 10.3
Analysts -
Fair Price Momentum 100.03 EUR
Fair Price DCF -

JREB Dividends

Currently no dividends paid

JREB Growth Ratios

Growth Correlation 3m 92.6%
Growth Correlation 12m 90.7%
Growth Correlation 5y -39.5%
CAGR 5y 0.23%
CAGR/Max DD 5y 0.01
Sharpe Ratio 12m 1.25
Alpha 0.44
Beta 0.054
Volatility 2.69%
Current Volume 2.2k
Average Volume 20d 0.6k
Stop Loss 103.9 (-3%)
What is the price of JREB shares?
As of July 16, 2025, the stock is trading at EUR 107.13 with a total of 2,214 shares traded.
Over the past week, the price has changed by -0.09%, over one month by +0.27%, over three months by +1.63% and over the past year by +5.25%.
Is JPMorgan s Ireland ICAV a good stock to buy?
Neither. Based on ValueRay´s Analyses, JPMorgan s Ireland ICAV is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 6.94 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JREB is around 100.03 EUR . This means that JREB is currently overvalued and has a potential downside of -6.63%.
Is JREB a buy, sell or hold?
JPMorgan s Ireland ICAV has no consensus analysts rating.
What are the forecasts for JREB share price target?
According to our own proprietary Forecast Model, JREB JPMorgan s Ireland ICAV will be worth about 108 in July 2026. The stock is currently trading at 107.13. This means that the stock has a potential upside of +0.84%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 108 0.8%